Xvivo Perfusion AB
(LTS:0RKL)
kr
471.13141
-2.4818 (-0.52%)
Market Cap: 15.12 Bil
Enterprise Value: 14.69 Bil
PE Ratio: 73.15
PB Ratio: 7.28
GF Score: 89/100 Q1 2020 Xvivo Perfusion AB Earnings Call Transcript
Apr 09, 2020 / 09:30AM GMT
Release Date Price:
kr124.31
(+12.59%)
Operator
Ladies and gentlemen, welcome to XVIVO Perfusion Report Webcast. I will now hand over to Magnus Nilsson, CEO. Please go ahead.
Magnus Nilsson;publ;MD;CEO
Xvivo Perfusion AB
()-&
Welcome to this 30th quarterly report of XVIVO Perfusion, the interim report January to March 2020. And I have with me Christoffer Rosenblad, the CFO. Christoffer?
Christoffer Rosenblad;publ;CFO
Xvivo Perfusion AB;Deputy CEO, Deputy MD & Board Secretary
()- -
Hello.
Magnus Nilsson;publ;MD;CEO
Xvivo Perfusion AB
()-&
Next slide, please. So first, the highlights of this very unusual Q1. We still have a strong cash position which is the primary message. So we have very limited cash consumption, cash consumption during Q1 in spite of a very heavy investment in R&D, as usual, and we end the quarter in a good financial position, SEK 159 million at the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot